A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The prescribing information for two respiratory syncytial virus (RSV ... (manufactured by Pfizer) and Arexvy (manufactured by GlaxoSmithKline), according to the FDA communication.

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly ... The Food and Drug Administration cleared GSK’s shot for adults aged 50 to 59 years who ...